Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.
[object Object] 
October 2020 in “Authorea (Authorea)” Men and women react differently to opioids, with hormones potentially influencing these differences.
3 citations,
May 2018 in “Experimental Dermatology” Young HS patients often have other physical and mental health issues, and research on HS covers a wide range of topics including genetics, triggers, treatments, and the need for more data.
4 citations,
January 2021 in “Archives of dermatological research” The study created a new model to better understand human hair growth and health.
May 2019 in “Australasian Journal of Dermatology” A new diagnostic tool for Vulvovaginal Lichen Planus is highly accurate, and updated treatments for various skin conditions, including melanoma and Hidradenitis Suppurativa, were discussed.
36 citations,
April 2016 in “British journal of dermatology/British journal of dermatology, Supplement” A substance called VIP might protect hair follicles from being attacked by the immune system, and problems with VIP signaling could lead to hair loss in alopecia areata.
[object Object] 
22 citations,
August 1999 in “Experimental Dermatology” Certain drugs can cause early hair growth in mice by affecting the nerves.